Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Interchangeability; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of interchange of vaccine products in a adult patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included Hepatitis a vaccine for prophylaxis. In FEB-2025, the patient received the 1st dose of Twinrix. On an unknown date, the patient received the 1st dose of Hepatitis a vaccine. In FEB-2025, an unknown time after receiving Twinrix, the patient experienced interchange of vaccine products (Verbatim: Interchangeability). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-APR-2025 The pharmacist stated that an adult patient (unknown specific age) received what it seems to be first dose of Hepatitis A vaccine (unknown brand name or lot number) on 2017 (unknown specific date), and on February 2025 (not specific date) the patient got first dose of Twinrix, which led to interchange of vaccine products. Since pharmacist was calling on behalf of another facility, they did not have patient demographics or additional details of the scenario.